NCT06353386 2026-03-13
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
Clinical Trials
23 trialsNCT06691984 2026-03-06
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Amgen
Phase 3 Recruiting
NCT07213674 2026-02-27
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Amgen
Phase 3 Recruiting
NCT05818683 2026-02-13
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT05701007 2026-01-29
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer
Completed
NCT02985957 2025-12-22
CheckMate 650
Bristol-Myers Squibb
Phase 2 Completed
NCT05005728 2025-07-17
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Xencor, Inc.
Phase 2 Completed
NCT06890832 2025-03-24
A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer
Jina Pharmaceuticals Inc.
Phase 2 Not yet recruiting
NCT04495179 2023-08-09
AARDVARC
AstraZeneca
Phase 2 Completed
NCT02485691 2022-05-27
CARD
Sanofi
Phase 4 Completed
NCT03419442 2020-10-22
Multi-academic Center Study of Xofigo Patients
Bayer
Completed
NCT02379390 2019-06-21
PRIMCAB
Sanofi
Phase 2 Terminated
NCT01308567 2019-06-05
FIRSTANA
Sanofi
Phase 3 Completed
NCT01718353 2017-11-20
TAXYNERGY
Sanofi
Phase 2 Completed
NCT01308580 2017-04-17
PROSELICA
Sanofi
Phase 3 Completed
NCT02441894 2017-01-24
PEGAZUS
Sanofi
Phase 4 Completed
NCT01083615 2016-10-12
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Achieve Life Sciences
Phase 3 Terminated
NCT01578655 2016-10-12
AFFINITY
Achieve Life Sciences
Phase 3 Completed
NCT01649635 2016-07-06
PROSPECTA
Sanofi
Phase 4 Completed
NCT01254279 2015-01-21
Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen
Sanofi
Phase 3 Completed
NCT01324583 2015-01-07
Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Sanofi
Phase 1 Completed
NCT01576029 2013-12-24
SWITCH
Sanofi
Phase 2 Completed
NCT00417079 2011-03-10
TROPIC
Sanofi
Phase 3 Completed